Format

Send to

Choose Destination
J Alzheimers Dis. 2018 Nov 23. doi: 10.3233/JAD-180634. [Epub ahead of print]

Systematic Multi-Domain Alzheimer's Risk Reduction Trial (SMARRT): Study Protocol.

Author information

1
University of California, San Francisco, San Francisco, CA, USA.
2
San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA.
3
Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.

Abstract

This article describes the protocol for the Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT), a single-blind randomized pilot trial to test a personalized, pragmatic, multi-domain Alzheimer's disease (AD) risk reduction intervention in a US integrated healthcare delivery system. Study participants will be 200 higher-risk older adults (age 70-89 years with subjective cognitive complaints, low normal performance on cognitive screen, and ≥ two modifiable risk factors targeted by our intervention) who will be recruited from selected primary care clinics of Kaiser Permanente Washington, oversampling people with non-white race or Hispanic ethnicity. Study participants will be randomly assigned to a two-year Alzheimer's risk reduction intervention (SMARRT) or a Health Education (HE) control. Randomization will be stratified by clinic, race/ethnicity (non-Hispanic white versus non-white or Hispanic), and age (70-79, 80-89). Participants randomized to the SMARRT group will work with a behavioral coach and nurse to develop a personalized plan related to their risk factors (poorly controlled hypertension, diabetes with evidence of hyper or hypoglycemia, depressive symptoms, poor sleep quality, contraindicated medications, physical inactivity, low cognitive stimulation, social isolation, poor diet, smoking). Participants in the HE control group will be mailed general health education information about these risk factors for AD. The primary outcome is two-year cognitive change on a cognitive test composite score. Secondary outcomes include: 1) improvement in targeted risk factors, 2) individual cognitive domain composite scores, 3) physical performance, 4) functional ability, 5) quality of life, and 6) incidence of mild cognitive impairment, AD, and dementia. Primary and secondary outcomes will be assessed in both groups at baseline and 6, 12, 18, and 24 months.

KEYWORDS:

Alzheimer’s disease; dementia; health promotion; integrated delivery of health care; risk reduction behavior

PMID:
30475764
DOI:
10.3233/JAD-180634

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center